Cargando…

Repositioning microbial biotechnology against COVID‐19: the case of microbial production of flavonoids

Coronavirus‐related disease 2019 (COVID‐19) became a pandemic in February 2020, and worldwide researchers try to tackle the disease with approved drugs of all kinds, or to develop novel compounds inhibiting viral spreading. Flavonoids, already investigated as antivirals in general, also might bear a...

Descripción completa

Detalles Bibliográficos
Autores principales: Goris, Tobias, Pérez‐Valero, Álvaro, Martínez, Igor, Yi, Dong, Fernández‐Calleja, Luis, San León, David, Bornscheuer, Uwe T., Magadán‐Corpas, Patricia, Lombó, Felipe, Nogales, Juan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7675739/
https://www.ncbi.nlm.nih.gov/pubmed/33047877
http://dx.doi.org/10.1111/1751-7915.13675
_version_ 1783611685178703872
author Goris, Tobias
Pérez‐Valero, Álvaro
Martínez, Igor
Yi, Dong
Fernández‐Calleja, Luis
San León, David
Bornscheuer, Uwe T.
Magadán‐Corpas, Patricia
Lombó, Felipe
Nogales, Juan
author_facet Goris, Tobias
Pérez‐Valero, Álvaro
Martínez, Igor
Yi, Dong
Fernández‐Calleja, Luis
San León, David
Bornscheuer, Uwe T.
Magadán‐Corpas, Patricia
Lombó, Felipe
Nogales, Juan
author_sort Goris, Tobias
collection PubMed
description Coronavirus‐related disease 2019 (COVID‐19) became a pandemic in February 2020, and worldwide researchers try to tackle the disease with approved drugs of all kinds, or to develop novel compounds inhibiting viral spreading. Flavonoids, already investigated as antivirals in general, also might bear activities specific for the viral agent causing COVID‐19, SARS‐CoV‐2. Microbial biotechnology and especially synthetic biology may help to produce flavonoids, which are exclusive plant secondary metabolites, at a larger scale or indeed to find novel pharmaceutically active flavonoids. Here, we review the state of the art in (i) antiviral activity of flavonoids specific for coronaviruses and (ii) results derived from computational studies, mostly docking studies mainly inhibiting specific coronaviral proteins such as the 3CL (main) protease, the spike protein or the RNA‐dependent RNA polymerase. In the end, we strive towards a synthetic biology pipeline making the fast and tailored production of valuable antiviral flavonoids possible by applying the last concepts of division of labour through co‐cultivation/microbial community approaches to the DBTL (Design, Build, Test, Learn) principle.
format Online
Article
Text
id pubmed-7675739
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-76757392020-11-19 Repositioning microbial biotechnology against COVID‐19: the case of microbial production of flavonoids Goris, Tobias Pérez‐Valero, Álvaro Martínez, Igor Yi, Dong Fernández‐Calleja, Luis San León, David Bornscheuer, Uwe T. Magadán‐Corpas, Patricia Lombó, Felipe Nogales, Juan Microb Biotechnol Minireviews Coronavirus‐related disease 2019 (COVID‐19) became a pandemic in February 2020, and worldwide researchers try to tackle the disease with approved drugs of all kinds, or to develop novel compounds inhibiting viral spreading. Flavonoids, already investigated as antivirals in general, also might bear activities specific for the viral agent causing COVID‐19, SARS‐CoV‐2. Microbial biotechnology and especially synthetic biology may help to produce flavonoids, which are exclusive plant secondary metabolites, at a larger scale or indeed to find novel pharmaceutically active flavonoids. Here, we review the state of the art in (i) antiviral activity of flavonoids specific for coronaviruses and (ii) results derived from computational studies, mostly docking studies mainly inhibiting specific coronaviral proteins such as the 3CL (main) protease, the spike protein or the RNA‐dependent RNA polymerase. In the end, we strive towards a synthetic biology pipeline making the fast and tailored production of valuable antiviral flavonoids possible by applying the last concepts of division of labour through co‐cultivation/microbial community approaches to the DBTL (Design, Build, Test, Learn) principle. John Wiley and Sons Inc. 2020-10-13 /pmc/articles/PMC7675739/ /pubmed/33047877 http://dx.doi.org/10.1111/1751-7915.13675 Text en © 2020 The Authors. Microbial Biotechnology published by Society for Applied Microbiology and John Wiley & Sons Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Minireviews
Goris, Tobias
Pérez‐Valero, Álvaro
Martínez, Igor
Yi, Dong
Fernández‐Calleja, Luis
San León, David
Bornscheuer, Uwe T.
Magadán‐Corpas, Patricia
Lombó, Felipe
Nogales, Juan
Repositioning microbial biotechnology against COVID‐19: the case of microbial production of flavonoids
title Repositioning microbial biotechnology against COVID‐19: the case of microbial production of flavonoids
title_full Repositioning microbial biotechnology against COVID‐19: the case of microbial production of flavonoids
title_fullStr Repositioning microbial biotechnology against COVID‐19: the case of microbial production of flavonoids
title_full_unstemmed Repositioning microbial biotechnology against COVID‐19: the case of microbial production of flavonoids
title_short Repositioning microbial biotechnology against COVID‐19: the case of microbial production of flavonoids
title_sort repositioning microbial biotechnology against covid‐19: the case of microbial production of flavonoids
topic Minireviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7675739/
https://www.ncbi.nlm.nih.gov/pubmed/33047877
http://dx.doi.org/10.1111/1751-7915.13675
work_keys_str_mv AT goristobias repositioningmicrobialbiotechnologyagainstcovid19thecaseofmicrobialproductionofflavonoids
AT perezvaleroalvaro repositioningmicrobialbiotechnologyagainstcovid19thecaseofmicrobialproductionofflavonoids
AT martinezigor repositioningmicrobialbiotechnologyagainstcovid19thecaseofmicrobialproductionofflavonoids
AT yidong repositioningmicrobialbiotechnologyagainstcovid19thecaseofmicrobialproductionofflavonoids
AT fernandezcallejaluis repositioningmicrobialbiotechnologyagainstcovid19thecaseofmicrobialproductionofflavonoids
AT sanleondavid repositioningmicrobialbiotechnologyagainstcovid19thecaseofmicrobialproductionofflavonoids
AT bornscheueruwet repositioningmicrobialbiotechnologyagainstcovid19thecaseofmicrobialproductionofflavonoids
AT magadancorpaspatricia repositioningmicrobialbiotechnologyagainstcovid19thecaseofmicrobialproductionofflavonoids
AT lombofelipe repositioningmicrobialbiotechnologyagainstcovid19thecaseofmicrobialproductionofflavonoids
AT nogalesjuan repositioningmicrobialbiotechnologyagainstcovid19thecaseofmicrobialproductionofflavonoids